Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Scan the QR code with your smartphone or visit the link below to explore this program. The ASCO Direct™ Highlights program reviews practice-changing data and other “hot topics” discussed at the premier clinical oncology conference in North America, including information about hematologic malignancies and thoracic, breast, gastrointestinal, genitourinary, gynecologic, and dermatologic …
June 3, 2023
6:00 PM to 9:00 PM (Local Time) Don’t miss this opportunity to network with professionals from across the state, discuss challenges unique to Iowa's oncology community, and share key takeaways from the ASCO Annual Meeting. This event is open to all multidisciplinary care providers in Iowa who are involved in the practice of oncology and hematology. For industry, this event is by invitation only for …
June 3, 2023
6:00 PM to 9:00 PM (Local Time) Don’t miss this opportunity to network with professionals from across the state, discuss challenges unique to Wisconsin's oncology community, and share key takeaways from the ASCO Annual Meeting. This event is open to all multidisciplinary care providers in Wisconsin who are involved in the practice of oncology and hematology. For industry, this event is by invitation …
ACCC recognizes National Cancer Survivors Day with stories from two survivors who are members of its staff.
MSCO Professional Development Workshop Saturday, July 15 | Radisson Blu Mall of America Minneapolis, MN Agenda Saturday 3:30 PM Registration and MSCO/MAYO Networking Reception 4:00 PM Welcome/ Introductions Balkrishna Jahagirdar, MBBS Education Chair, Minnesota Society of Clinical Oncology 4:05 PM Navigating Billing and Coding in Your Early Career: Practical Insights …
Abstracts assess gaps in patient awareness of NSCLC biomarker test timing, the role of a precision medicine steward, perceptions and use of RPM technology in rural cancer programs Rockville, MD – The Association of Community Cancer Centers (ACCC) today announced the five abstracts and a poster presentation that will be showcased at the American Society of Clinical Oncology (ASCO) Annual Meeting June …
ASSOCIATION OF COMMUNITY CANCER CENTERS 1 Introduction In the last decade, oral oncolytics have transformed the treatment landscape of Chronic Lymphocytic Leukemia (CLL). At the time of this publication, six oral agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of CLL: acalabrutinib, ibrutinib, duvelisib, idelalisib, zanubrutinib, and …
Breaking down the social stigma that is often still associated with seeking mental health services is key to making cancer care clinicians and staff feel a "sense of safety" and that they will not be penalized for accessing mental health services.
Dr. Barbara Schmidtman shares why taking time off this spring or summer is important for leaders and their teams' self-care and job satisfaction.
A C C C ’ S C A L L T O A C T I O N : D E L I V E R Y O F P S Y C H O S O C I A L C A R E I N O N C O L O G Y S U M M I T ASSOCIATION OF COMMUNITY CANCER CENTERS Program Background The burden of cancer is far greater than the diagnosis of a single tumor. When patients receive a cancer diagnosis, every facet of their life—physical, mental, emotional, social, …
New Molecular Entities • None Changes in Labeled Indications • Polivy® (polatuzumb vedotin) --Genentech’s antibody-drug conjugate (ADC), which came to market with an accelerated approval for use (after at least two prior therapies) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), has now gained FDA’s approval for treating newly diagnosed patients. The …
PowerPoint Presentation May 11, 2023 TxSCO Update Overview: Notable Updates 2 Federal • PHE expires today, May 11th • In-office dispensers and mail order drugs • Telehealth • Medicaid enrollment drop • USPSTF Recommends Biennial Mammograms at age 40 • ACS CAN Report: Cancer deaths by congressional district • EOM: the latest State • Update …
ACCCBuzz spoke with Erika Siegrist at Luminis Health Research Institute to learn more about how technology has helped expand patient access to cancer clinical trials.
New Molecular Entities • None Changes in Labeled Indications • Polivy® (polatuzumb vedotin) --Genentech’s antibody-drug conjugate (ADC), which came to market with an accelerated approval for use (after at least two prior therapies) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), has now gained FDA’s approval for treating newly diagnosed patients. The …
In 2022, ACCC conducted a survey to measure patient, caregiver, and provider perceptions and adoption of messaging tools, electronic questionnaires, and connected devices used to track and monitor symptoms during cancer treatment.
Scan the QR code with your smartphone or visit the link below to explore this program. The ASCO Direct™ Highlights program reviews practice-changing data and other “hot topics” discussed at the premier clinical oncology conference in North America, including information about hematologic malignancies and thoracic, breast, gastrointestinal, genitourinary, gynecologic, and dermatologic …
1 Mazyar Shadman, MD MPH Associate Professor Fred Hutch Cancer Center and University of Washington Seattle, WA Immunotherapy for Lymphoma 2Fred Hutchinson Cancer Center Research funding from: Mustang Bio, BMS, Pharmacyclics, Genentech, AbbVie,TG Therapeutics, BeiGene, AstraZeneca, Genmab, MorphoSys/Incyte, Vincerx Consulting for: AbbVie, Genentech, AstraZeneca, …
Fred Hutchinson Cancer Center Community Cancer Care Report Updates Hutchinson Institute for Cancer Outcomes Research (HICOR) Veena Shankaran MD, MS (Co-Director) Scott Ramsey MD, PhD (Director) Fred Hutchinson Cancer Center HICOR Mission Improve the effectiveness of cancer prevention, early detection and treatment services in ways that reduce the economic and human burden …
New Molecular Entities • None Changes in Labeled Indications • Polivy® (polatuzumb vedotin) --Genentech’s antibody-drug conjugate (ADC), which came to market with an accelerated approval for use (after at least two prior therapies) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), has now gained FDA’s approval for treating newly diagnosed patients. The …